Literature DB >> 28602395

Reprogramming of the Tumor in the Hypoxic Niche: The Emerging Concept and Associated Therapeutic Strategies.

Guan-Zhong Qiu1, Ming-Zhu Jin2, Jin-Xiang Dai3, Wei Sun4, Ji-Hong Feng5, Wei-Lin Jin6.   

Abstract

Hypoxia exerts a profound impact on diverse aspects of cancer biology. Increasing evidence has revealed novel functions of hypoxia in cancer cell epigenomics, epitranscriptomics, metabolism, and intercellular communication, all hotspots of cancer research. Several drugs have been developed to target intratumoral hypoxia and have entered clinical trials to treat refractory tumors. However, direct targeting of hypoxia signaling still has limitations in the clinic with regard to cancer progression and resistance to therapy. Comprehensive understanding of the molecular mechanisms by which hypoxia reshapes tumors and their microenvironment, as well as how tumor cells adapt to and thrive in hypoxic conditions, will therefore continue to be a focus of cancer research and will provide new directions for hypoxic tumor treatment.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HIF1α; cancer; epigenetics; exosome; hypoxia; metabolism

Mesh:

Substances:

Year:  2017        PMID: 28602395     DOI: 10.1016/j.tips.2017.05.002

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  48 in total

1.  DEC1 is required for anti-apoptotic activity of gastric cancer cells under hypoxia by promoting Survivin expression.

Authors:  Yanfei Jia; Rui Hu; Ping Li; Yan Zheng; Yunshan Wang; Xiaoli Ma
Journal:  Gastric Cancer       Date:  2017-12-04       Impact factor: 7.370

2.  Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes.

Authors:  Anna Julia Wiecek; Daniel Hadar Jacobson; Wojciech Lason; Maria Secrier
Journal:  Front Cell Dev Biol       Date:  2021-07-09

3.  TET2-dependent IL-6 induction mediated by the tumor microenvironment promotes tumor metastasis in osteosarcoma.

Authors:  Hitoshi Itoh; Tsuyoshi Kadomatsu; Hironori Tanoue; Masaki Yugami; Keishi Miyata; Motoyoshi Endo; Jun Morinaga; Eisuke Kobayashi; Takeshi Miyamoto; Ryoma Kurahashi; Kazutoyo Terada; Hiroshi Mizuta; Yuichi Oike
Journal:  Oncogene       Date:  2018-03-08       Impact factor: 9.867

4.  SMAD family member 3 (SMAD3) and SMAD4 repress HIF2α-dependent iron-regulatory genes.

Authors:  Xiaoya Ma; Nupur K Das; Cristina Castillo; Ayla Gourani; Ansu O Perekatt; Michael P Verzi; Yatrik M Shah
Journal:  J Biol Chem       Date:  2019-01-18       Impact factor: 5.157

5.  Recapitulating Tumor Hypoxia in a Cleanroom-Free, Liquid-Pinning-Based Microfluidic Tumor Model.

Authors:  Jeong Min Oh; Hydari Masuma Begum; Yao Lucia Liu; Yuwei Ren; Keyue Shen
Journal:  ACS Biomater Sci Eng       Date:  2022-06-09

6.  Galectin-1 activates carbonic anhydrase IX and modulates glioma metabolism.

Authors:  Maheedhara R Guda; Andrew J Tsung; Swapna Asuthkar; Kiran K Velpula
Journal:  Cell Death Dis       Date:  2022-06-30       Impact factor: 9.685

7.  Nanomedicine-Enabled Modulation of Tumor Hypoxic Microenvironment for Enhanced Cancer Therapy.

Authors:  Jinping Wang; Beilu Zhang; Jingyu Sun; Yuhao Wang; Hongjun Wang
Journal:  Adv Ther (Weinh)       Date:  2019-09-30

Review 8.  Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance.

Authors:  Fang Wei; Dan Wang; Junyuan Wei; Niwen Tang; Le Tang; Fang Xiong; Can Guo; Ming Zhou; Xiaoling Li; Guiyuan Li; Wei Xiong; Shanshan Zhang; Zhaoyang Zeng
Journal:  Cell Mol Life Sci       Date:  2020-07-11       Impact factor: 9.261

Review 9.  Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.

Authors:  Ya-Nan Pi; Wen-Cai Qi; Bai-Rong Xia; Ge Lou; Wei-Lin Jin
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 8.786

Review 10.  Immunogenic Cell Death-Based Cancer Vaccines.

Authors:  Ming-Zhu Jin; Xi-Peng Wang
Journal:  Front Immunol       Date:  2021-05-31       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.